NCT01770886已完成1 期
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety and tolerability of UE2343 in healthy male/female subjects
研究概览
简要总结
A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects between 18 and 65 years of age (inclusive).
- •Female subject is postmenopausal or surgically sterilized or had a hysterectomy.
- •Female subject with negative pregnancy test.
- •Male subjects willing to use an effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months afterwards.
- •Subject with a Body Mass Index (BMI) of 18-30 kg/m
- •Body Mass Index = Body weight (kg) / [Height (m)]
- •Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values or results suggesting an infectious or other systemic disorder. The parameters to be measured will include those shown in Appendix
- •The Simbec normal ranges are shown in Appendix
- •Subject with a negative urinary drugs of abuse screen (Appendix 2) (N.B. a positive alcohol result may be repeated at the discretion of the Investigator).
- •Subject with negative HIV and Hepatitis B and C results.
- •Subject with no clinically significant abnormalities in 12-lead electrocardiogram (ECG).
- •no clinically significant abnormalities in vital signs.
- •willing and able to comply with the requirements of the protocol.
- •satisfy a medical examiner about fitness to participate in the study.
- •provide written informed consent to participate in the study.
- •Smokers are eligible to participate in the study.
排除标准
- •Relevant abnormality in medical history or on examination, including history of dementia, or other psychiatric, neurological, immunological, respiratory or cardiovascular disorder. Particularly exclude subjects with signs of peripheral neuropathy. Abnormal laboratory findings suggesting the presence of a systematic disorder.
- •Participation in a clinical study of an unlicensed drug in the previous 4 months, or a marketed drug study within the previous 3 months. (N.B. washout period between trials defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
- •Known allergies, including allergy to chemicals like and excipients associated with UE
- •Recent or clinically significant history of drug or alcohol abuse.
- •Blood donation greater than 500 ml in the previous 3 months.
- •Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
- •Receipt of regular prescribed medication within 7 days of the first study day and / or receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7 days of the first study day. Subjects taking long lasting drugs more than 7 days before the study may be excluded at the physician's discretion. Inclusion of subjects who have taken over the counter drugs during this period will be reviewed on a case-by-case basis in relation to the safety aspects and objectives of this study.
研究组 & 干预措施
UE2343
Active Comparator
Oral capsule
干预措施: UE2343 (Drug)
Placebo
Placebo Comparator
Oral capsule
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability of UE2343 in healthy male/female subjects
时间窗: At each dose
Days 1-2 at each dose: * 12 lead ECG * Vital signs * Symptom led clinical assessment (day 1 only) * Routine laboratory assessments Days 3-6 at each dose: * 12 lead ECG * Vital signs * Routine laboratory assessments Day 10 at each dose: * 12 lead ECG * Vital signs * Routine laboratory assessments * Physical examination * Pregnancy test
次要结局
- Pharmacokinetic parameters of UE2343 and pharmacodynamic exposure(At each dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy SubjectsHIV-1 InfectionNCT04802811Jiangsu HengRui Medicine Co., Ltd.37
已完成
1 期
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB SubjectsChronic Hepatitis bNCT04464733Jiangsu HengRui Medicine Co., Ltd.146
Unknown
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B PatientsChronic Hepatitis BNCT04480294Jiangsu HengRui Medicine Co., Ltd.108
Unknown
1 期
A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy SubjectsHealthy SubjectsNCT05347758Shandong Suncadia Medicine Co., Ltd.106
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789Healthy VolunteersNCT03163550Achaogen, Inc.40